[go: up one dir, main page]

SG10201912394VA - Improved nanoparticle delivery systems - Google Patents

Improved nanoparticle delivery systems

Info

Publication number
SG10201912394VA
SG10201912394VA SG10201912394VA SG10201912394VA SG10201912394VA SG 10201912394V A SG10201912394V A SG 10201912394VA SG 10201912394V A SG10201912394V A SG 10201912394VA SG 10201912394V A SG10201912394V A SG 10201912394VA SG 10201912394V A SG10201912394V A SG 10201912394VA
Authority
SG
Singapore
Prior art keywords
delivery systems
nanoparticle delivery
improved nanoparticle
improved
systems
Prior art date
Application number
SG10201912394VA
Other languages
English (en)
Inventor
Leon Wan
Winnie Lui
Paul Tardi
Lawrence Mayer
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Publication of SG10201912394VA publication Critical patent/SG10201912394VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201912394VA 2015-07-15 2016-07-14 Improved nanoparticle delivery systems SG10201912394VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562192973P 2015-07-15 2015-07-15
US201562252396P 2015-11-06 2015-11-06

Publications (1)

Publication Number Publication Date
SG10201912394VA true SG10201912394VA (en) 2020-02-27

Family

ID=57757767

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201912394VA SG10201912394VA (en) 2015-07-15 2016-07-14 Improved nanoparticle delivery systems

Country Status (17)

Country Link
US (4) US10285951B2 (ru)
EP (1) EP3322404A4 (ru)
JP (2) JP2018521068A (ru)
KR (1) KR20180029242A (ru)
CN (1) CN107920985B (ru)
AU (2) AU2016294617B2 (ru)
BR (1) BR112018000217A2 (ru)
CA (1) CA2991062C (ru)
CO (1) CO2018000146A2 (ru)
HK (1) HK1251159A1 (ru)
IL (1) IL256797B (ru)
MA (1) MA42458A (ru)
MX (1) MX2018000611A (ru)
RU (1) RU2018105494A (ru)
SG (1) SG10201912394VA (ru)
WO (1) WO2017011685A1 (ru)
ZA (1) ZA201800130B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116077439A (zh) 2016-04-29 2023-05-09 西奈山伊坎医学院 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
CN112218619A (zh) * 2017-11-20 2021-01-12 西奈山伊坎医学院 通过治疗性纳米生物制剂组合物抑制驯化免疫
WO2019178443A1 (en) * 2018-03-16 2019-09-19 University Of Massachusetts Yeast cell wall particle encapsulation of biodegradable pro-payloads
KR102088663B1 (ko) * 2018-03-20 2020-03-13 한국세라믹기술원 친수성 및 소수성 약물의 동시 전달을 위한 온도민감성 나노스펀지 플랫폼 및 이의 용도
WO2020123481A1 (en) * 2018-12-10 2020-06-18 Celator Pharmaceuticals Inc. Combination formulations of taxanes and mtor inhibitors
KR20220045203A (ko) * 2019-08-13 2022-04-12 펩티노보 바이오파마, 인크. 암 치료에 따른 화학요법-유도된 말초 신경병증 치료를 위한 palm
WO2022055542A1 (en) * 2020-09-10 2022-03-17 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing pd-1 antagonist prodrugs useful in the treatment of cancer and methods thereof
US11859021B2 (en) 2021-03-19 2024-01-02 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
WO2025199353A1 (en) * 2024-03-21 2025-09-25 Purdue Research Foundation Nanoparticulate formulations and foliar administration thereof in the treatment and prevention of citrus greening disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1432402E (pt) 2001-10-03 2007-02-28 Celator Pharmaceuticals Inc Composições para administração de combinações de fármacos
EP1448231A1 (en) 2001-11-19 2004-08-25 Control Delivery Systems, Inc. Topical delivery of codrugs
AU2003223226A1 (en) * 2003-02-20 2004-09-17 University Of Connecticut Health Center Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease
AU2005269800B8 (en) * 2004-07-19 2011-12-01 Celator Pharmaceuticals, Inc. Particulate constructs for release of active agents
AU2006235538A1 (en) * 2005-04-12 2006-10-19 Wisconsin Alumni Research Foundation Micelle composition of polymer and passenger drug
EP2222278B1 (en) * 2007-11-28 2015-04-08 Celator Pharmaceuticals, Inc. Improved taxane delivery system
BRPI1014854A2 (pt) * 2009-03-30 2016-05-03 Cerulean Pharma Inc "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados"
CA2779843A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
EA201390144A1 (ru) * 2010-08-20 2013-06-28 Серулин Фарма Инк. Конъюгаты терапевтический пептид-полимер, частицы, композиции и связанные с ними способы
EA201390740A1 (ru) 2010-11-19 2013-12-30 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Способ лечения с использованием ингибитора braf
AU2012249553A1 (en) * 2011-04-29 2013-10-24 Selecta Biociences, Inc. Tolerogenic synthetic nanocarriers for allergy therapy
US20140308363A1 (en) * 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
DE102011109374A1 (de) * 2011-08-04 2013-02-07 Bock 1 Gmbh & Co. Kg Stuhl mit Wippmechanik
KR102062025B1 (ko) * 2014-06-30 2020-01-03 타베다 세라퓨틱스, 인코포레이티드 표적화된 콘주게이트 및 입자 및 그것의 제형

Also Published As

Publication number Publication date
US20240366519A1 (en) 2024-11-07
JP2018521068A (ja) 2018-08-02
BR112018000217A2 (pt) 2018-09-04
RU2018105494A3 (ru) 2019-12-17
CA2991062C (en) 2023-06-20
US20180207104A1 (en) 2018-07-26
EP3322404A4 (en) 2019-03-20
RU2018105494A (ru) 2019-08-15
US20190209484A1 (en) 2019-07-11
AU2016294617A1 (en) 2018-01-25
CN107920985A (zh) 2018-04-17
KR20180029242A (ko) 2018-03-20
JP2022033751A (ja) 2022-03-02
US10285951B2 (en) 2019-05-14
CO2018000146A2 (es) 2018-04-19
AU2016294617B2 (en) 2021-09-16
CN107920985B (zh) 2022-03-01
AU2021286353A1 (en) 2022-01-20
HK1251159A1 (zh) 2019-01-25
CA2991062A1 (en) 2017-01-19
IL256797B (en) 2021-05-31
MX2018000611A (es) 2018-09-06
MA42458A (fr) 2018-05-23
US20210052508A1 (en) 2021-02-25
US11413253B2 (en) 2022-08-16
WO2017011685A1 (en) 2017-01-19
IL256797A (en) 2018-06-28
ZA201800130B (en) 2018-12-19
EP3322404A1 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
GB201802837D0 (en) Awrosol delivery system
ZA201502203B (en) Nano particulate delivery system
EP3212173A4 (en) Delivery systems
GB201600232D0 (en) Fluid delivery system
ZA201800130B (en) Improved nanoparticle delivery systems
GB201514510D0 (en) Delivery vehicle
SG11201801783VA (en) Intracellular delivery vehicle
GB201703170D0 (en) Improved goods delivery systems
GB201407614D0 (en) Content delivery system
HUE047207T2 (hu) Bortezomib alapú adagolórendszer
GB201600229D0 (en) Fluid delivery system
IL247106A0 (en) Material delivery system
GB2559712B (en) Solid state delivery system
GB201715590D0 (en) Delivery system
IL246874A0 (en) drug delivery system
GB201420903D0 (en) Fluids delivery system
GB2532245B (en) Cardioplegic agent delivery system
GB201509934D0 (en) Nanoparticles
GB201517654D0 (en) Object delivery system
GB201600236D0 (en) Fluid delivery system
GB201614126D0 (en) Delivery vehicle
GB201522636D0 (en) Delivery system
IL256995A (en) Transdermal delivery system
IL256994A (en) Transdermal delivery system
GB201721699D0 (en) Delivery system